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mg S or placebo (P) included iet and was persued for 2.3 years. In the P- 
group, serum lipide remained unchon0ed, while the S-group showed a 35*/0 
LDL-C decrease. 20510ts (81%) had a 2 r~ coronary angiography and 203 
(80%) were evalusble by QCA. In the ,S-Group, corunary progression (per 
patient mean change in minimum lumen diameter (t~minD) was significantly 
less than in the P-Group (-0,02 mm vs -0.1 ram; p = 0.0022). 
In the S group (n = 103), the individual absolute LDL-C-levels achieved 
therapeutically were slgnlfcantly correlated with the correspaoding MLD 
decreases (R = 0.241; g < 0.015). Dividing the correlated parametem in 
tertilea of their distribution curves, "pmgrassion" (mean MLD-lass of > +0.04 
ram) o¢cured in 45.4% in the upper (>_ 115 mg/di), in 34.4o/o in the medium 
(95-114 mg/dl) and in 23.5*/= in the lowest LDL-C-ledile (_< 54 mg/dl). The 
corresponding rates for "No Change, Regression'(mean MLD-ICSs < +0.04 
mm) were 54.6°/0, 08.6% and 76.5*/0. 
Conclusion: In patients with elevated LDL-C-levels, CAD-progreesion can 
be slowed down significantly by lipid lowering with S. The extent ef pro- 
greseion reduction is correlated with the absolute LDL-C-leveis achieved 
therapeutically; based on the tedile-dependent progression rates, LDL-C 
target levels should be below 100 mg/dl. 
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~ '5"~ Scandinavian Simvaststm Study (4S): Survival 
Cost-Effectiveness (CE) of Cholesterol Lowering 
Treatment 
Brace Kinoslan, Henry Glick, J Sanford Schwartz for the 4S Group. 
University of Pennsylvania, Philadelphia, PA 
In contrast to the demonstrated clinica~ benefits of cholesteml-mod@ing 
drugs in lOtS with CAD and moderate cholesterol elevation, less evidence is 
available about CE. We assessed the CE of eimvastatin Rx usin~ a simulation 
model integrating data from 4S. 
Life expectancies were estimated from 4S survival using Weibull failure 
time models. Cardiovascular hospitalization and drug use were derived from 
,IS data. Cost and benefds were discounted 5"/0 per yr. Medical service costs 
were estimated using adjusted Medicare DRG & RBRV8 reimbursement 
(lower bound) and Medstet allowed charges (upper bound); drug costs were 
estimated using average wholesale price plus dispensing fees. CE analyses 
were performed for both the 5 yr 4S observation period and projected for 
lifetime Rx. 
During the 4S follow-up, treated pat]ants lived an additional 0.065 ym 
(Discounted: 0.053 yrs [95% Ch 0.019-0.087]). Simvastatin cost was part~ally 
offset by reduced medical care expenditures. Net costs of Rx were $808 
(Medstat) - $3,526 (Medicare) over the 5 yr ,IS observation period. Projected 
incremental survival for lifetime Rx was 2.22 yrs (Discounted: 0.926 yrs [95% 
CI: 0.561-1.29]). Expected net Rx cost was $6,798 (Medstet) - $11,045 
(Medicare), with coet/YOLS of $7,340-$11,927 [95*/,, Ch $5,918-$44,517]. 
While the CE of simvastatin Rx in pts with CAD and moderate cholesterol 
intervention is within the range of accepted medical interventions when the 
analysis is restricted to the 5-year 4S observation period, long-term Rx is 
even more costoeffective, asthe greatest benefds occur after the initial 5 yrs. 
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[ ' -~ '~ Atheroeclero$1s Plaque Regression on the Thoracic 
Aorta Assessed by Transe~ophegeal 
Echocardlegraphy in Patients With Oyspllpidemla 
and Coronery Artery Dleease 
Miguel Zabaigoitia, William Linn, Rosario Mercado, Lori Oneschuk, 
Kamn Vanden~oud, Sheri Y. Noftestad, John Come,° Robert A. O'Rourke. 
University of Texas HIth Science Ctr, San Antonio, TX 
Transesophageal echocardiography (TEE) provides an excellent means to 
characterize athemsdemtic plaques (AP) on ascending (AA), transverse 
{TA), and descending aorta (DA). To determine if TEE can be used to evaluate 
AP modification, 10 male pts (mean age 63 yrs) with dyslipldemia nd 
documented coronary artery disease were treated eccording to National 
Chefestoml Education Program. AP areas were planimetered at 2 cm apart 
along the AA, TA, and DA from biplane TEE at baseline and at 12 moneys 
of therapy. Exact distance from the incisors was indicated to assure that 
comparisons on the same patient were taken at the same site. Total plaque 
area (TPA) index was calculated by adding all areas suitable for cempadson 
and divided by the number of entries. Results: When TPA index at 12 months 
was compared to baseline, it changed from 1.54 cm ~ to 1.15 cn~, p < 
0.01, a 25*/0 reduction; total cholesterol changed from 209 mg/di to 170 
mg/di, p < 0.001, a 19% reduction, low density llpupmtaio (LDL-cholasterol) 
changed from 140 mg/di to 109 mg/dl, p < 0.002, a 22% reduction; and total 
cholesterol/high density lipaprotein ratio changed from 5.6 to 4.8, p < 0.08, 
a 14% reduction. TPA index and LDL-cholasterol reductions correlated well 
r = 0.76, SEE = 0.19, p < 0.05. Conc/us/on: Agrassive lipid lowering therapy 
results in a 25=/, reduction on AP of the thoracic aorta after 12 months. 
Reduction of LDL-cholesterol correlates well with AP regression. TEE is a 
useful non-invasive technique to evaluate AP moo~tication by lipid lowering 
treatment. 
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[ -7~- ' ]  RegmsMon of Atheroma Seen With intravascular 
Ultrasound: A Placebo Controlled Study of the 
Effect of Gemfibrozil on Peripheral Atherosclerosis 
Andrew N. Deaner, Jeff Ball, Arzu A. Cubskco, Simon Meg~y, Peter 
J. Scott, Paul Brooksby, Mohen Lal, Mchan Sivanathan, Gordon J. Witlir, ms. 
Killingbeck Hospital, Leeds, UK 
The Killingbac~ Regression of Atheroma Study (KRAS) was a double blind 
placebo ~ntmlled study of the effect of gemfibrez, plus I'~oid lowering diet 
remus lipid lowering diet only on atheroma in the distal aorta and lliao ar- 
teries of patients with coronary artery d '~sa  and modemt~ raised liplds 
(mean total cholesterol = 6.8 retool/I). Serial cress-sectional images of these 
vessels were recorded at 2 mm intervals using a 6 French, 20 MHz intravas- 
cuter ultrasound (IVUS) catheter during a controlled pull back in 39 patients 
(male 26, ages 38-70). Patients were given dietary advice and randomized 
to treatment with ge~l  600 log bd or placetlo. After a mean of 371 
days the 31 patients (17 in gemf'(mo:,q group) who completed the study 
undenvent repeat IVU$ imaging. A total of 1144 segments of artery were 
matched accord~g to ~ position oi bifiacaffon paints and measurements of 
cress-sectional rea of atherema made by compete~ed planimeW. Base- 
line demographics, phystcsI end lipid data were well matched between the 
bealment groups. In the gerrvF'mmzfl group signif'¢arrt eductions compared 
to the diet only group, were seen in total cholesterol (9%, p = 0.03), triglyCo 
endas (55%, p = 0.0001) and LDtJI-IDL ratio (26./o, p = 0.62), a signtf'¢ant 
increase in HDL cholesterol level (27°/= p = 0.05) was also seen. No overall 
significant change in the mean o'nss-sectiorml area of efherema was se~.n 
in the d'vet only greup but them v,'es an g.85% decrease of this n'masumme-vt 
in the gemflbrozil group (p = 0.009). Analysis of cruse-sectional plaque aP.~ 
changes within individual patients howed significant (p < 0.05) ~;on  
of > 5% ef plaque in 5 of the ~ ' 1  greup but only 1 of the o-ret only 
group. 
Thus, this study using repeated IVUS measurements of plaque crcss- 
sectional area showed significant r~-~r~ion of peripheral etheroma in pa- 
tients treated with gemlromzil plus I~id lowering diet. 
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[7 -~- ]  Pravaststin Reduces Transient Myocardial Ischemla 
in Patients With Angina Pectoris and Significant 
GAD 
Ad J van Boven, J Wouter Juk.,mla, Am'lko H Zwinderman, Albert 
VG Bnnchke, Kong I Lie for the REGRESS Study. The In tenm/~ 
Institute, ICIN, Utmch~ Thoraxcent~, Univ. Hospital, Groningen. 
The Nethe4anOs 
Usual anti-anginal Imetment, including PTCA and CABG, will relieve symp- 
toms, but a cemplete abolishment of Transient Myocardial Ischemla (TMI) is 
not always aCained. We hypathes~.ed that pravastatin 40 mg (P) in add~ion 
to conven~onal theral~ may reduce TMI end studied its 2 year ~ 
effect in 768 patients from the REGRESS study, using 48 horn ambulatory 
ECG's. In this placebo con~relled stody only men wifh angina puctods, doc- 
umented coronanj ariew dtsease and a cholesterol bo{ween 4 and 8 mmol/I 
were incloded. Separate randO~T&~ blocks ware made from pls who un- 
~ respec~ PTCA, CABG onnedical menagement. Ouring Honer 
monitoring antHschan~ medica~ was continued. To analyze the ~ect 
of P we used a logistic re@-~ medel wt~ random effects. Dudng the 
study the parceetage of patients with TMI ~ frem 28% to 19% with 
P and increased from 19% to 23% with placebo. The odde ratio for TMI of 
P versus placebo was 0.62 (95% Cl 0.41-0.93; p = 0.621). Total duration 
of ischem~ and ischcnnic burden were reduced with 38 n~'l and 19 mm.min 
with P and 9 rain aod 8 mm.ndn with placebo, p = 0.017 and 0.0088 respac- 
tively. P reduced TMI d,~,~'ta optimal anti-anginal lmatment. These data on 
the anti-ischendc action of P are in rme with ils reduction in clinical events in 
REGRESS. 
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~ Lowering "Desirable" Levels Cholesterol ~n~proves 
Flow-Mediated Vasoactivity in Healthy, Middle-Aged 
Men 
Robert A. Vogel, M~rv C. Cormtti, Ga~ D. Plothick. University of Maryland 
School of Med'~ne, B "~=mora, MD 
Cunent Na~nal Cholesterol Educe, on Program g~errnes consider desir- 
